Three outstanding research and development projects in the areas of mobility and safety, design and production as well as in active substance research in medicine are nominated for the Federal President's Award for Innovation and Technology 2015. The teams selected by the jury for the final round were announced today at a press conference at the Deutsches Museum in Munich.
The nominees are:
Dipl.-Ing. Ralf Bornefeld (spokesperson)
Dr.-Ing. Walter Hartner
Dr. rer. nat. Rudolf Lachner
Infineon Technologies AG, Munich and Regensburg
with their project "Car radar technology - A lifesaver goes into series production".
The team with their two fundamental technical innovations - in the manufacture of radar chips and their further processing - has dramatically lowered production costs of active safety systems and thereby paved the way for their use in the mass car market. This could further reduce the number of fatalities and serious injuries in traffic-related accidents.
Dipl.-Ing. (FH) Peter Sander (spokesperson)
Prof. Dr.-Ing. Claus Emmelmann*
Dipl.-Ing. (FH) Frank Herzog**
Airbus Operations GmbH, Hamburg
*LZN Laser Zentrum Nord GmbH, Hamburg
**Concept Laser GmbH, Lichtenfels
with their work on "3D printing in civil aircraft construction - A production revolution takes off".
The three nominees have improved the technology of 3D printing to such an extent that it can also be used to manufacture metal aircraft components subjected to high mechanical and thermal loading. The new process makes their manufacture more affordable, more flexible and environmentally friendly. The innovative process uses a laser and is expected to revolutionize production processes.
Prof. Dr. rer. nat. habil. Johannes-Peter Stasch
Dr. med. Reiner Frey
Prof. Dr. med. Ardeschir Ghofrani*
Bayer Pharma AG, Wuppertal
with their developments on "A relief for heart and lung - From nitroglycerine to innovative therapies".
These research scientists have discovered and developed a treatment for two forms of pulmonary hypertension. Research on the new active substance Riociguat is based on 130 years of treating angina pectoris with nitroglycerine. The innovative drug can provide considerable relief from the serious illness for affected patients. For some, the drug from Germany is the first drug therapy ever available.
Among the criteria for the Deutscher Zukunftspreis are in addition to innovative research also the product's marketability and the creation of jobs. The German President's Award for Innovation in Science and Technology is endowed with € 250,000 in prize money.
The jury will meet on December 2 to determine this year's prizewinners. Federal President Joachim Gauck will award the Deutscher Zukunftspreis 2015 this year at a gala even in Berlin.
All images are available in our newsroom for downloading.